Methylation in aml: Clinical applications

Research output: Chapter in Book/Report/Conference proceedingChapter


Epigenetic therapy is a recognized central therapeutic strategy widely used in treatment of myelodysplatic syndrome (MDS). The approved agents, decitabine and azacytidine, are DNA hypomethylating agents that have been shown in randomized phase III trials to have clinical benefit in MDS patients. New research is investigating the use of these drugs in the setting of acute myeloid leukemia (AML) treatment, especially in older patients. Early studies are demonstrating promising results for the use of decitabine and azacytidine in treatment of AML. Other novel epigenetic/hypomethylating agents as well as chemotherapy combinations including hypomethylating agents represent an active area of research in treatment of AML patients.

Original languageEnglish (US)
Title of host publicationTargeted Therapy of Acute Myeloid Leukemi
PublisherSpringer New York
Number of pages18
ISBN (Electronic)9781493913930
ISBN (Print)9781493913923
StatePublished - Jan 1 2015


  • AML
  • Azacytidine
  • Decitabine
  • Hypomethylator

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Methylation in aml: Clinical applications'. Together they form a unique fingerprint.

Cite this